Intensity Therapeutics
INTS4.2000.48% ( +0.020 )
Intensity Therapeutics (INTS)
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer...
- Open
- 4.000
- High
- 4.325
- Low
- 3.995
- Prev. Close
- 4.180
- Volume
- 64.75K
- Turnover
- 268.99K
- Avg Price
- 4.155
- Bid/Ask Ratio
- --
- Amplitude
- 7.89%
- 52wk High
- 43.500
- Volume Ratio
- 4.70
- Turnover Ratio
- 2.79%
Intensity Therapeutics Analyst Rating
View MoreForecast & Rating
May 19, 2026Price forecast
$24.80490.48%
Forecast & RatingStrong buy
5analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 07:07 AM
Intensity Therapeutics schedules Q2 financial results conference call
- Global Report · Jul 24 at 04:13 AM
Life Beyond the Megacaps: The Complex Reality of 2026's Market Misfits
- StockTitan · Jul 14 at 10:45 PM
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | INTS Stock News
- Global Report · Jul 9 at 09:02 PM
PayPal's Crypto Pivot and Meta's Chip Push: Inside the Payments Reshuffle
- Global Report · Jul 9 at 05:02 AM
US Small-Cap Capital Deployment Accelerates Amid Tech and Biotech Pivots
- PUBT · Jul 1 at 07:04 AM
Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trial
